Skip to main content
Hit enter to search or ESC to close
Close Search
Menu
Company
Team
Psybrary™
Pipeline
Investors
Investor Overview
Press Releases
Media Coverage
Events + Presentations
Stock Information
SEC Filings
Corporate Governance
News Alerts
Contact
twitter
facebook
linkedin
Investors
Media Coverage
NASDAQ: ENVB
Overview
Press Releases
Media Coverage
Events + Presentations
Stock Information
SEC Filings
Corporate Governance
News Alerts
Media Coverage
Hope For Non-Hallucinogenic Neuroplastogens [Drug Discovery Online]
March 9, 2026
The Patent War That Wasn’t: How Enveric’s Legal Win Reframes the Neuroplastogen Race [Pharma Tech News]
February 25, 2026
Gilgamesh Withdraws Patent Fight Against Enveric After $1.2 Billion AbbVie Deal, CEO Says Key Drug Claims Now Uncontested [Benzinga]
February 25, 2026
AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy [Microdose]
February 25, 2026
What Enveric Biosciences’ EB-003 data reveal about separating benefit from hallucinations [Pharma Device News]
February 24, 2026
Beyond the Trip: Enveric’s EB-003 and the Next Phase of Psychedelic-Inspired Drug Design [Meditech Today]
February 19, 2026
Enveric Biosciences stock soars after revealing new data on lead drug candidate [Investing.com]
February 19, 2026
Breaking News: Enveric Unveils Proprietary Receptor Data That Could Redefine Psychedelic Drug Design [Medium]
February 19, 2026
Enveric Advances Lead Drug With New Findings On Key Brain Receptor Signals [Benzinga]
February 19, 2026
The next wave of psychedelics focuses on brain rewiring without the trip [Drug Discovery News]
February 18, 2026
1
2
3
…
16
›
Close Menu
Company
Team
Psybrary™
Pipeline
Investors
Investor Overview
Press Releases
Media Coverage
Events + Presentations
Stock Information
SEC Filings
Corporate Governance
News Alerts
Contact
twitter
facebook
linkedin
